Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma

Epidermal growth factor receptor (EGFR) is involved in the progression of many cancer types and represents an important therapeutic target.

[1]  S. Sone,et al.  Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. , 2003, Oncology research.

[2]  T. Asano,et al.  Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. , 2004, The Journal of urology.

[3]  I. Bassukas,et al.  Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact. , 1997, European urology.

[4]  R. Figlin,et al.  Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Erdoğan,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.

[6]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[7]  R. Stahel,et al.  A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma , 2006, Cancer Chemotherapy and Pharmacology.

[8]  I. Giannopoulou,et al.  Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas , 2008, Breast Cancer Research.

[9]  A. Ravaud,et al.  Amplification of epidermal growth factor receptor gene in renal cell carcinoma. , 2010, European journal of cancer.

[10]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[12]  G. Niehans,et al.  Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  A. Hussain,et al.  A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[14]  M. Bittner,et al.  Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. , 2007, Lung cancer.

[15]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[16]  A. Gotoh,et al.  EGFR mRNA is Upregulated, but Somatic Mutations of the Gene are Hardly Found in Renal Cell Carcinoma in Japanese Patients , 2005, Pharmaceutical Research.

[17]  F. Hirsch,et al.  Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Waldman,et al.  Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. , 1997, Human pathology.

[19]  H. Hollema,et al.  Expression of Epidermal Growth Factor Receptor (EGFR) and Activated EGFR Predict Poor Response to (Chemo)radiation and Survival in Cervical Cancer , 2009, Clinical Cancer Research.

[20]  C. Magi-Galluzzi,et al.  The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. , 2007, Clinical genitourinary cancer.

[21]  F. Waldman,et al.  EGF‐r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization , 1998, The Journal of pathology.

[22]  M. Berger,et al.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.

[23]  S. Pomer,et al.  Concomitant overexpression of the EGFR and erbB‐2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis , 1996, International journal of cancer.

[24]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[25]  S. Maeda,et al.  Amplification and overexpression of the epidermal growth factor receptor gene in human renal‐cell carcinoma , 1990, International journal of cancer.

[26]  B. Ljungberg,et al.  Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy , 2004, Urological Research.

[27]  S. Advani,et al.  Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7. , 2001, Cancer genetics and cytogenetics.

[28]  P. Stattin,et al.  Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients , 2010, Clinical Cancer Research.

[29]  M. Kuczyk,et al.  Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. , 2005, Anticancer research.

[30]  R. Figlin,et al.  Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  F. Waldman,et al.  TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. , 2010, Cancer letters.

[33]  R. Klausner,et al.  Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Samlowski,et al.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.